Business Today
Subscribe
PMS TodayUS NewsIndiaUPSTARTWeatherBT ShortsNRIEducationElection
BT India 100BT GolfBT Mindrush
Search

COMPANIES

No Data Found

NEWS

No Data Found
Advertisement
News
markets
stocks
Concord Drugs Ltd
Concord Drugs Ltd

Concord Drugs Ltd Share Price

  • Sector: Pharmaceuticals (Small Cap)
  • Volume: 11,121
Aug 08, 2025 Closed
  • BSE
Share
  • Whatsapp
  • Twitter
  • Facebook
₹54.73
₹-1.11 (-1.99%)
54.73Low
Today’s Performance
56.95High
26.10Low
52 Week’s Performance
67.00High

bt_logoStock Performance

  • 1 Day-1.99%
  • 1 Week-2.27%
  • 1 Month-1.35%
  • 3 Months78.74%
  • 6 Months57.81%
  • 1 Year44.67%
  • 3 Years26.32%
  • 5 Years30.30%

bt_logoStock Summary

  • Face Value (₹)10.00
  • Beta0.54
  • 52-Week Low (₹)26.10
  • 52-Week High (₹)67.00
  • Price-to-Book (X)*1.60
  • Dividend Yield (%)-
  • Price-to-Earnings (P/E) (X)*160.97
  • Earnings Per Share (₹)0.34
  • Market Cap (₹ Cr.)*54.73
* Values as of last close price

bt_logoCOMPETITORS

BT TV

Haseeb Drabu Vs N K Singh: Bureaucracy, Federalism & Power Play | BT India@1002:28Haseeb Drabu Vs N K Singh: Bureaucracy, Federalism & Power Play | BT India@100
Gadkari: E20 Cuts Mileage Slightly but Doesn’t Damage Vehicles, Petroleum Lobby Fuelling Fear5:23Gadkari: E20 Cuts Mileage Slightly but Doesn’t Damage Vehicles, Petroleum Lobby Fuelling Fear
Leadership Drives State Growth: Arvind Panagariya On India's Top States By 20473:36Leadership Drives State Growth: Arvind Panagariya On India's Top States By 2047
Centre Vs States: N K Singh & Haseeb Drabu Debate Fiscal Federalism | BT India@1006:35Centre Vs States: N K Singh & Haseeb Drabu Debate Fiscal Federalism | BT India@100
India’s Diplomatic Game Plan Against U.S. Trade Pressures | Neelkanth Mishra3:28India’s Diplomatic Game Plan Against U.S. Trade Pressures | Neelkanth Mishra
Gen Beta’s New Money Mindset | Rachana Ranade, AssetYogi & More At BT India@10035:53Gen Beta’s New Money Mindset | Rachana Ranade, AssetYogi & More At BT India@100
The Sunrise Sectors That Will Drive India’s Growth | Rajat Dhawan At India@10020:52The Sunrise Sectors That Will Drive India’s Growth | Rajat Dhawan At India@100
US Tariff Hypocrisy? Amul & GTRI Hit Back On Dairy, Agri Access | BT India@1002:00US Tariff Hypocrisy? Amul & GTRI Hit Back On Dairy, Agri Access | BT India@100
McKinsey’s Rajat Dhawan on How India’s Innovation Will Drive $30T Economy1:26McKinsey’s Rajat Dhawan on How India’s Innovation Will Drive $30T Economy
Shaping A Healthy Future For Bharat | Shobana Kamineni, Ashutosh Raghuvanshi At BT India@10021:07Shaping A Healthy Future For Bharat | Shobana Kamineni, Ashutosh Raghuvanshi At BT India@100
View more

bt_logoFAQ's

What was Concord Drugs Ltd share price previously?
Concord Drugs Ltd share price was down by -1.99% from the previous closing price of ₹55.84.
Who are peers of Concord Drugs Ltd?
The peers of Concord Drugs Ltd are Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Torrent Pharmaceuticals Ltd, Cipla Ltd, Mankind Pharma Ltd, Dr Reddys Laboratories Ltd, Zydus Lifesciences Ltd.
Who is/are the promoter/promoters of Concord Drugs Ltd?
The promotor/promotors of Concord Drugs Ltd are S Nagi Reddy, K Ramchandra Reddy, Koni Reddy, S. Nagavenkata Hareesh, S. Manoj Kumar Reddy, Summela Kasu, Namratha Nagla.
What has been 52-week high of Concord Drugs Ltd stocks?
The highest price of Concord Drugs Ltd stock is ₹67.00 in the last 52-week.
What is the share price of Concord Drugs Ltd (CONCORD) today on BSE?
As on Aug 08, 2025 Concord Drugs Ltd (CONCORD)’s share price on BSE is Rs 54.73
What is the market cap of Concord Drugs Ltd (CONCORD)?
The current market capitalisation of Concord Drugs Ltd (CONCORD) is 54.73 crores
What is Concord Drugs Ltd Share symbol?
The symbol of Concord Drugs Ltd is .
What is the PE ratio of Concord Drugs Ltd (CONCORD)?
The current PE ratio of Concord Drugs Ltd (CONCORD) is 160.97.
What is the PB ratio of Concord Drugs Ltd (CONCORD)?
The current PB ratio of Concord Drugs Ltd (CONCORD) is 1.60.
Today’s High & Low share prices of Concord Drugs Ltd (CONCORD) on BSE?
Today, the share price of Concord Drugs Ltd (CONCORD) on BSE touched a high of Rs 56.95 and a low of Rs 54.73
What price did Concord Drugs Ltd (CONCORD) shares open on the BSE today?
On BSE, the share price of Concord Drugs Ltd (CONCORD) opened at Rs 56.95
What is the 52-week high of Concord Drugs Ltd (CONCORD)?
The 52-week high price of Concord Drugs Ltd (CONCORD) is Rs 67.00
What is the 52-week low of Concord Drugs Ltd (CONCORD)?
The 52-week low price of Concord Drugs Ltd (CONCORD) is Rs 26.10

bt_logoAbout Concord Drugs

Concord Drugs Ltd, incorporated in the year 1995, has its registered office in Survey No 249 Brahmanapally V, Hayathnagar M, Ranga Reddy, Telangana, 501511, 91-40-24036379. The main industry in which Concord Drugs Ltd operates is Pharmaceuticals - Indian - Bulk Drugs & Formln.

Auditor/Auditors for Concord Drugs Ltd is/are Pundarikashyam and Associates. In the main management, S Nagi Reddy is chairman and Namratha Nagla is the company secretary for Concord Drugs Ltd.

  • SNR
    S Nagi ReddyChairman & Managing Director
  • KRR
    K Ramchandra ReddyIndependent Director
  • KR
    Koni ReddyWhole Time Director & Chief Financial Officer
  • SNH
    S. Nagavenkata HareeshIndependent Director
  • SMKR
    S. Manoj Kumar ReddyWhole-time Director
  • SK
    Summela KasuIndependent Director
  • NN
    Namratha NaglaCompany Sec. & Compli. Officer

bt_logoTop Stories

DATA SOURCES: Corporate data, historical price & volume data published on this website have been sourced from CMOTS Internet Technologies Pvt. Ltd. BSE Quotes and NSE Quotes have been sourced from BSE Limited and NSE Data & Analytics Limited, respectively. All timestamps reflected here are in IST (Indian Standard Time). Stock Analysis section has been sourced from the mentioned partners.

DISCLAIMER: Any and all content on this website, including the tools/ analysis, is provided to you only for convenience and on an “as-is, as-available” basis without representation and warranties of any kind. The content and any output of such tools/ analysis is for informational purposes only and should not be relied upon or construed as investment advice or guarantee for any specific performance/ returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this website, you agree to the Terms of Service and Privacy Policy.